Search Results

left posterior neck tumor was 3 cm. During the third week of treatment, the patient experienced rapid onset of a macular erythematous rash that quickly grew to cover approximately 90% of her body. This was accompanied by daily fevers ranging from 102

with MPNs experience a unique constellation of physical symptoms, such as pruritus, night sweats, bone and splenic pain, fatigue, and fevers. Symptom burden can be similar in severity to the experience of patients with metastatic cancer or acute myeloid

cytogenetic risk group. Thus, clofarabine shows encouraging results in older patients, including those with unfavorable karyotypes. However, the treatment is myelosuppressive, with most patients requiring hospitalization for neutropenic fever or infection

experienced disease control for 7 months with the combination of chemotherapy and sorafenib. Case Presentation A 65-year-old man presented to the emergency room who had experienced worsening pain in both calves during the past 2 to 3 weeks, fever and

dabrafenib at 150 mg twice daily and trametinib at 2 mg daily, with a Karnofsky performance status (KPS) of 50 and an ECOG performance status (PS) of 3. Treatment was complicated by fevers and a rash that responded to steroids. The steroids were titrated to

development of symptoms that are suggestive of influenza (eg, high fever, coryza, myalgia, dry cough), especially during community outbreaks. Both the Infectious Diseases Society of America (2007) and CDC guidelines (2011) recommend antiviral treatment with

-related autoimmune retinopathy and was referred to an oncologist for further evaluation. She had no detectable antiretinal antibodies. She was a nonsmoker with no significant past medical history. She denied weight loss, fever, abdominal pain, dysuria, vaginal

. Crawford J Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 7. Ohno R Tomonaga M Kobayashi T

/chemotherapy arm experienced more neutropenia and fever; however, overall, treatment discontinuations were similar in both arms: 69% of patients on the R 2 arm and 71% of those on the rituximab/chemotherapy arm completed treatment. 13 Final data showed that R 2

Symptoms of disease are often restricted to the involved organ, and 15% to 30% of patients present with fever, malaise, microcytic anemia, weight loss, thrombocytosis, elevated erythrocyte sedimentation rate, or polyclonal hypergammaglobulinemia. 3 Surgery